PERTZYE is the same formulation previously marketed as PANCRECARB® MS-16 and is the only pancreatic enzyme replacement therapy (PERT) containing bicarbonate-buffered enteric-coated microspheres.

Indications & Usage

Warnings & Precautions

Adverse Reactions

PERTZYE is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions.

Fibrosing colonopathy is associated with high-dose use of pancreatic enzyme replacement. Exercise caution when doses of PERTZYE exceed 2,500 lipase units/kg of body weight per meal (or greater than 10,000 lipase units/kg of body weight per day).

The most common adverse reactions (≥ 10% of patients treated with PERTZYE) are diarrhea, dyspepsia, and cough.

To avoid irritation of oral mucosa, do not chew PERTZYE or retain in the mouth.

Hyperuricemia may develop. Consider monitoring uric acid levels in patients with hyperuricemia, gout, or renal impairment.

There is theoretical risk of viral transmission with all pancreatic enzyme products including PERTZYE.

Exercise caution when administering pancrelipase to a patient with a known allergy to proteins of porcine origin.

-

-

-

-

-

copyright 2016, Digestive Care, Inc.,

design by Matthew Kramer Art & Design, all rights reserved